Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy
Status:
Not yet recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) can be the
final option for achieving complete revascularization in diffuse coronary artery disease
patients. Since the exposure of subendothelial tissue to the blood flow after CE, the
coagulation cascade can be activated, resulting in the increased risk of graft failure.
Therefore, anticoagulation with warfarin in this group of patients might be beneficial.
However, evidence is limited. This study aims to compare the clinical outcomes between dual
antiplatelet therapy with or without warfarin after CE+CABG.